埃博霉素作用机制和临床药理的研究进展  

Recent Progress of Epothilones in Mechanism and Clinical Pharmacology

作　　者：徐晓威[1] 徐寒梅[1] 顾觉奋[1] 

机构地区：[1]中国药科大学生命科学与技术学院,南京210009

出　　处：《抗感染药学》2013年第2期81-85,共5页Anti-infection Pharmacy

摘　　要：埃博霉素是由纤维堆囊菌分离得到的一类16元大环内酯类抗生素,其具有比紫衫烷类更强的微管稳定作用和抗肿瘤活性,对紫杉烷类耐药的肿瘤细胞仍具有较好的细胞毒性;综述2010年—2012年间关于埃博霉素的产生菌、生物合成和发酵表达、抗肿瘤机制以及临床药理研究的文献资料,并对其研究进展作一分析。ABSTRACTS Epothilones were 16-membered macrolide antibiotics isolated from Sorangium cellulosum. They had more potent stabilization of microtubule and activity of anti-tumor than that of taxanes, and was cytotoxic to the tax- ane-resistant malignancy as well. The research literature referred to producing strain, biosynthesis and fermentation, an- ti-tumor mechanism and clinical pharmacology of epothilones situation between 2010 and 2012 was reviewed and the research progress of epothilones was analyzed. KEY WORDS epothilone; sorangium cellulosum; stabilization ofmicrotubule; anti-tumour; clinical trials

关 键 词：埃博霉素 纤维堆囊菌 微管稳定 抗肿瘤 临床 

分 类 号：R979.14[医药卫生—药品]